Back to Journals » Cancer Management and Research » Volume 13

Corrigendum

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]

       

Authors Li X , Chen W, Liu K, Zhang S, Yang R, Liu K, Li D, Huang Y 

Received 9 March 2021

Accepted for publication 9 March 2021

Published 16 March 2021 Volume 2021:13 Pages 2515—2516

DOI https://doi.org/10.2147/CMAR.S310256

Download Article [PDF] 


Li X, Chen W, Liu K, et al. Cancer Manag Res. 2020;12:8081–8091


The authors have advised Figure 5D and 5E (on page 8088) is incorrect due to layout negligence during figure disposal. The correct Figure is shown below.

Read the original article

Creative Commons License © 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]